MindBio Therapeutics Corp. (WF6.F)
| Previous close | 0.0312 |
| Open | 0.0342 |
| Bid | 0.0286 x N/A |
| Ask | 0.0504 x N/A |
| Day's range | 0.0342 - 0.0342 |
| 52-week range | 0.0088 - 0.0850 |
| Volume | |
| Avg. volume | 6,272 |
| Market cap | 5.91M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
CAMBRIDGE, Mass., May 14, 2024--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has signed a non-binding term sheet to out-license a class of Novel Psilocin Prodrugs ("NPP") to Vancouver, BC-based MindBio Therapeutics (CNSX: MBIO)("MindBio"), a clinical stage biopharma company, which
- GlobeNewswire
InvestmentPitch Media Video Discusses MindBio Therapeutics' Commencement of MB22001 Phase 2 Clinical Trial in World's First Take-Home Microdosing Study for Patients with Depression
VANCOUVER, British Columbia, Aug. 25, 2023 (GLOBE NEWSWIRE) -- MindBio Therapeutics (CSE:MBIO) (FSE:WF6), an Australia-based biotech/biopharma company creating novel and emerging treatments for mental health conditions, has initiated dosing of MB22001 to patients in a landmark microdosing study for depression. This groundbreaking trial represents a global precedent and stands as the sole clinical trial authorized for the take-home usage of LSD. A Media Snippet accompanying this announcement is a
- GlobeNewswire
InvestmentPitch Media Video Discusses MindBio Therapeutics’ Clinical Trials of LSD-Microdosing Reveals Significant Positive Impact on Quality of Sleep
VANCOUVER, British Columbia, June 15, 2023 (GLOBE NEWSWIRE) -- MindBio Therapeutics (CSE:MBIO) (FSE:WF6), a Melbourne, Australia-based leader in microdosing psychedelic medicines, announced a significant breakthrough based on sleep data collected during randomized controlled trials of LSD-Microdosing. The trials involved 80 participants, and a total of 3,231 nights of sleep data were analyzed. A Media Snippet accompanying this announcement is available by clicking on the image or link below: For
